Cipla Of India Markets Generic of Bayer's Kidney Cancer Drug
This article was originally published in PharmAsia News
Executive SummaryIndia's Cipla has launched at home a generic version of Nexavar (sorafenib) marketed by Germany's Bayer to treat kidney cancer
You may also be interested in...
Sharing "Schering" Link Gets Bayer And Cadila To Talk Joint Venture; Deal Spanning Market To Manufacturing Likely In Final Stages
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot
Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.